Cargando…
Docosahexaenoic acid supplementation in gestational diabetes mellitus and neonatal metabolic health biomarkers
BACKGROUND AND OBJECTIVE: Gestational diabetes mellitus (GDM) “programs” an elevated risk of metabolic dysfunctional disorders in the offspring, and has been associated with elevated leptin and decreased adiponectin levels in cord blood. We sought to assess whether docosahexaenoic acid (DHA) supplem...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069675/ https://www.ncbi.nlm.nih.gov/pubmed/37020805 http://dx.doi.org/10.3389/fnut.2023.1089131 |
_version_ | 1785018894702870528 |
---|---|
author | Xu, Ya-Jie Wang, Wen-Juan Zhang, Qiu-Yi Yang, Meng-Nan Zhang, Lin He, Hua Dong, Yu Ouyang, Fengxiu Gao, Ying Zhang, Jun Zheng, Tao Luo, Zhong-Cheng |
author_facet | Xu, Ya-Jie Wang, Wen-Juan Zhang, Qiu-Yi Yang, Meng-Nan Zhang, Lin He, Hua Dong, Yu Ouyang, Fengxiu Gao, Ying Zhang, Jun Zheng, Tao Luo, Zhong-Cheng |
author_sort | Xu, Ya-Jie |
collection | PubMed |
description | BACKGROUND AND OBJECTIVE: Gestational diabetes mellitus (GDM) “programs” an elevated risk of metabolic dysfunctional disorders in the offspring, and has been associated with elevated leptin and decreased adiponectin levels in cord blood. We sought to assess whether docosahexaenoic acid (DHA) supplementation in GDM affects neonatal metabolic health biomarkers especially leptin and adiponectin. METHODS: In a randomized controlled trial, singleton pregnant women with de novo diagnosis of GDM at 24–28 weeks of gestation were randomized to dietary supplementation of 500 mg DHA per day (intervention, n = 30) until delivery or standard care (control, n = 38). The primary outcomes were cord blood leptin and total adiponectin concentrations. Secondary outcomes included high-molecular-weight (HMW) adiponectin and insulin-like growth factor-1 (IGF-1) concentrations in cord blood, maternal glycemic control post-intervention and birth weight (z score). In parallel, 38 euglycemic pregnant women were recruited for comparisons of cord blood biomarkers. RESULTS: There were no significant differences in cord serum leptin, total and HMW adiponectin and IGF-1 concentrations between DHA supplementation and control groups (all p > 0.05). Maternal fasting and 2-h postprandial blood glucose levels at 12–16 weeks post-intervention were similar between the two groups. The newborns in the DHA group had higher birth weight z scores (p = 0.02). Cord blood total and HMW adiponectin concentrations were significantly lower in GDM vs. euglycemic pregnancies. CONCLUSION: Docosahexaenoic acid supplementation at 500 mg/day in GDM women did not affect neonatal metabolic biomarkers including leptin, adiponectin and IGF-1. The results are reassuring in light of the absence of influence on neonatal adipokines (leptin and adiponectin), and potential benefits to fetal growth and development. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov, NCT03569501. |
format | Online Article Text |
id | pubmed-10069675 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100696752023-04-04 Docosahexaenoic acid supplementation in gestational diabetes mellitus and neonatal metabolic health biomarkers Xu, Ya-Jie Wang, Wen-Juan Zhang, Qiu-Yi Yang, Meng-Nan Zhang, Lin He, Hua Dong, Yu Ouyang, Fengxiu Gao, Ying Zhang, Jun Zheng, Tao Luo, Zhong-Cheng Front Nutr Nutrition BACKGROUND AND OBJECTIVE: Gestational diabetes mellitus (GDM) “programs” an elevated risk of metabolic dysfunctional disorders in the offspring, and has been associated with elevated leptin and decreased adiponectin levels in cord blood. We sought to assess whether docosahexaenoic acid (DHA) supplementation in GDM affects neonatal metabolic health biomarkers especially leptin and adiponectin. METHODS: In a randomized controlled trial, singleton pregnant women with de novo diagnosis of GDM at 24–28 weeks of gestation were randomized to dietary supplementation of 500 mg DHA per day (intervention, n = 30) until delivery or standard care (control, n = 38). The primary outcomes were cord blood leptin and total adiponectin concentrations. Secondary outcomes included high-molecular-weight (HMW) adiponectin and insulin-like growth factor-1 (IGF-1) concentrations in cord blood, maternal glycemic control post-intervention and birth weight (z score). In parallel, 38 euglycemic pregnant women were recruited for comparisons of cord blood biomarkers. RESULTS: There were no significant differences in cord serum leptin, total and HMW adiponectin and IGF-1 concentrations between DHA supplementation and control groups (all p > 0.05). Maternal fasting and 2-h postprandial blood glucose levels at 12–16 weeks post-intervention were similar between the two groups. The newborns in the DHA group had higher birth weight z scores (p = 0.02). Cord blood total and HMW adiponectin concentrations were significantly lower in GDM vs. euglycemic pregnancies. CONCLUSION: Docosahexaenoic acid supplementation at 500 mg/day in GDM women did not affect neonatal metabolic biomarkers including leptin, adiponectin and IGF-1. The results are reassuring in light of the absence of influence on neonatal adipokines (leptin and adiponectin), and potential benefits to fetal growth and development. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov, NCT03569501. Frontiers Media S.A. 2023-03-20 /pmc/articles/PMC10069675/ /pubmed/37020805 http://dx.doi.org/10.3389/fnut.2023.1089131 Text en Copyright © 2023 Xu, Wang, Zhang, Yang, Zhang, He, Dong, Ouyang, Gao, Zhang, Zheng and Luo. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Nutrition Xu, Ya-Jie Wang, Wen-Juan Zhang, Qiu-Yi Yang, Meng-Nan Zhang, Lin He, Hua Dong, Yu Ouyang, Fengxiu Gao, Ying Zhang, Jun Zheng, Tao Luo, Zhong-Cheng Docosahexaenoic acid supplementation in gestational diabetes mellitus and neonatal metabolic health biomarkers |
title | Docosahexaenoic acid supplementation in gestational diabetes mellitus and neonatal metabolic health biomarkers |
title_full | Docosahexaenoic acid supplementation in gestational diabetes mellitus and neonatal metabolic health biomarkers |
title_fullStr | Docosahexaenoic acid supplementation in gestational diabetes mellitus and neonatal metabolic health biomarkers |
title_full_unstemmed | Docosahexaenoic acid supplementation in gestational diabetes mellitus and neonatal metabolic health biomarkers |
title_short | Docosahexaenoic acid supplementation in gestational diabetes mellitus and neonatal metabolic health biomarkers |
title_sort | docosahexaenoic acid supplementation in gestational diabetes mellitus and neonatal metabolic health biomarkers |
topic | Nutrition |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069675/ https://www.ncbi.nlm.nih.gov/pubmed/37020805 http://dx.doi.org/10.3389/fnut.2023.1089131 |
work_keys_str_mv | AT xuyajie docosahexaenoicacidsupplementationingestationaldiabetesmellitusandneonatalmetabolichealthbiomarkers AT wangwenjuan docosahexaenoicacidsupplementationingestationaldiabetesmellitusandneonatalmetabolichealthbiomarkers AT zhangqiuyi docosahexaenoicacidsupplementationingestationaldiabetesmellitusandneonatalmetabolichealthbiomarkers AT yangmengnan docosahexaenoicacidsupplementationingestationaldiabetesmellitusandneonatalmetabolichealthbiomarkers AT zhanglin docosahexaenoicacidsupplementationingestationaldiabetesmellitusandneonatalmetabolichealthbiomarkers AT hehua docosahexaenoicacidsupplementationingestationaldiabetesmellitusandneonatalmetabolichealthbiomarkers AT dongyu docosahexaenoicacidsupplementationingestationaldiabetesmellitusandneonatalmetabolichealthbiomarkers AT ouyangfengxiu docosahexaenoicacidsupplementationingestationaldiabetesmellitusandneonatalmetabolichealthbiomarkers AT gaoying docosahexaenoicacidsupplementationingestationaldiabetesmellitusandneonatalmetabolichealthbiomarkers AT zhangjun docosahexaenoicacidsupplementationingestationaldiabetesmellitusandneonatalmetabolichealthbiomarkers AT zhengtao docosahexaenoicacidsupplementationingestationaldiabetesmellitusandneonatalmetabolichealthbiomarkers AT luozhongcheng docosahexaenoicacidsupplementationingestationaldiabetesmellitusandneonatalmetabolichealthbiomarkers |